Key Highlights

  • Novo Nordisk (NYSE:NVO) posted third-quarter 2026 adjusted operating profit of DKK 31,720 million, up 27% at constant exchange rates, on net sales of DKK 79,195 million, up 4%.
  • Wegovy pill sales hit DKK 5,394 million in the quarter after launches in the US, the UAE, the UK and Germany, and four more countries have been added since.
  • The 2026 outlook was raised, with adjusted sales growth and adjusted operating profit growth now guided at minus 2% to plus 2% at constant exchange rates.
  • Reported operating profit fell 3% to DKK 23,011 million after DKK 8.7 billion of non-cash impairments, so the adjusted and reported pictures diverge.

What Novo Reported

Novo Nordisk (NYSE:NVO) released third-quarter results on November 4, 2026, and shares were reported up roughly 5% to 6% in early trading. Net sales grew 6% in Danish kroner and 4% at constant exchange rates. Adjusted operating profit rose 34% in kroner and 27% at constant rates, flattered by a weak comparison with about DKK 9 billion of transformation costs booked in the third quarter of 2025. Reported operating profit declined because of DKK 4.6 billion of Impairment on ziltivekimab and DKK 4.1 billion linked to reshaping the Manufacturing network. Over nine months, net sales reached DKK 254,506 million, up 13% at constant rates, while adjusted net sales were DKK 227,746 million, up 2%.

The Wegovy Pill and the Pipeline

The oral Wegovy launch is the visible engine. Quarterly sales reached DKK 5,394 million, and the company says it took more than 50% of branded obesity new patient starts in the US for Wegovy overall. An Ozempic pill launched in the US in May, and weekly new prescriptions are about 100% higher than pre-launch levels for Rybelsus. Pipeline readouts included 21% weight loss at week 68 for CagriSema 1.0 mg in the REDEFINE 9 obesity study, and 12.4% weight loss against 9.1% for tirzepatide 5 mg in REIMAGINE 5. A US launch of CagriSema is planned for early 2027, subject to approval. Frehemgo, known as denecimig, received a positive CHMP opinion on September 17, with European launches expected around the turn of the year and a US launch in the first half of 2027, pending a regulatory decision.

Risks and What the Outlook Really Means

The raised outlook is still a narrow range. Adjusted sales and adjusted operating profit are guided between minus 2% and plus 2% at constant rates, which describes a stabilising year rather than a growing one. The release does not restate the prior ranges, so the size of the increase cannot be measured from it. Nine-month adjusted net sales were flat in kroner. Other risks include pricing pressure, competition from Eli Lilly in obesity, Supply and launch costs, and further impairments. A share buyback programme began on May 6, 2026. Novo Nordisk (NYSE:NVO) also has a Danish listing, so currency moves feed into the figures investors see. No consensus comparison was available in the material reviewed, so this article claims no beat or miss.

Where Things Stand

Novo Nordisk (NYSE:NVO) has momentum from the Wegovy pill, which generated DKK 5,394 million of sales in a single quarter, and a 27% adjusted profit gain at constant rates. Whether the run continues is still open. The full-year range of minus 2% to plus 2% implies a flat year, reported profit took a hit from impairments and rivals are pushing hard. Watch weekly prescriptions, the CagriSema US decision expected in early 2027 and the next outlook update.